Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2010-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2009.04112.xPMID 19681818
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and epidemiological research

  2011cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

  2011cited by this paper
• Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

  2009cited by this paper
• Development of primary varicella infection during infliximab treatment for psoriasis.

  2009cited by this paper
• European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

  2009cited by this paper
• Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection.

  2009cited by this paper
• Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study.

  2009cited by this paper
• Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

  2009cited by this paper
• Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C

  2008cited by this paper
• Etanercept treatment in a hemodialysis patient with severe cyclosporine‐resistant psoriasis and hepatitis C virus infection

  2008cited by this paper
• Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B.

  2008cited by this paper
• Risk factors for opportunistic infections in patients with inflammatory bowel disease.

  2008cited by this paper
• Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

  2008cited by this paper
• Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy.

  2008cited by this paper
• The Effect of Methotrexate and Anti–Tumor Necrosis Factor Therapy on the Risk of Lymphoma in Rheumatoid Arthritis in 19,562 Patients During 89,710 Person-Years of Observation

  2008cited by this paper
• 970 Risk of Lymphoma Associated with Anti-TNF Agents for the Treatment of Crohn's Disease: A Meta-Analysis

  2008cited by this paper
• From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.

  2008cited by this paper
• Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment

  2008cited by this paper
• Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports

  2008cited by this paper
• Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease

  2008cited by this paper
• Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.

  2008cited by this paper
• Statements from the Taormina expert meeting on occult hepatitis B virus infection.

  2008cited by this paper
• Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab

  2008cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008

  2008cited by this paper
• Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease.

  2008cited by this paper
• Intrahepatic expression of pro-inflammatory cytokine mRNAs and interferon efficacy in chronic hepatitis C.

  2008cited by this paper
• Recurrent Varicella in an Adult Psoriasis Patient Treated with Etanercept

  2008cited by this paper
• Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.

  2008cited by this paper
• Hepatitis B virus reactivation during therapy with etanercept in an HBsAg‐negative and anti‐HBs‐positive patient

  2008cited by this paper
• Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis

  2008cited by this paper
• Genital HPV Lesions and Molluscum Contagiosum Occurring in Patients Receiving Anti-TNF-α Therapy

  2008cited by this paper
• Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

  2008cited by this paper
• Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.

  2008cited by this paper
• Screening differences and risk of cervical cancer in inflammatory bowel disease

  2008cited by this paper
• Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.

  2008cited by this paper
• Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis

  2007cited by this paper
• Development of varicella during adalimumab therapy

  2007cited by this paper
• Combination therapy with cyclosporine A and anti-TNF-α agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

  2007cited by this paper
• Congenital Chloride Diarrhea: A Missed Diagnosis in an Adult Patient

  2007cited by this paper
• Successful etanercept use in an HIV-positive patient with rheumatoid arthritis.

  2007cited by this paper
• Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection

  2007cited by this paper
• Occult hepatitis B and infliximab-induced HBV reactivation.

  2007cited by this paper
• Long‐term treatment with methotrexate or tumor necrosis factor α inhibitors does not increase epstein‐barr virus load in patients with rheumatoid arthritis

  2007cited by this paper
• Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.

  2007cited by this paper
• Successful Treatment of Chronic Hepatitis C With Pegylated Interferon, Ribavirin, and Infliximab in a Patient with Crohn's Disease

  2007cited by this paper
• Infliximab in the Treatment of an HIV Positive Patient with Reiter ' s Syndrome

  2007cited by this paper
• Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient.

  2007cited by this paper
• Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab.

  2007cited by this paper
• Use of infliximab to treat psoriatic arthritis in HIV-positive patients.

  2007cited by this paper
• The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease

  2007cited by this paper
• Infliximab and the risk of latent viruses reactivation in active Crohn's disease

  2007cited by this paper
• Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis.

  2007cited by this paper
• Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease.

  2007cited by this paper
• The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.

  2007cited by this paper
• Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

  2007cited by this paper
• Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).

  2006cited by this paper
• Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C.

  2006cited by this paper
• Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.

  2006cited by this paper
• Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

  2006cited by this paper
• Safe and effective application of anti-TNF-α in a patient infected with HIV and concomitant Crohn’s disease

  2006cited by this paper
• Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody.

  2006cited by this paper
• Etanercept therapy in two patients with psoriasis and concomitant hepatitis C.

  2006cited by this paper
• Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.

  2006cited by this paper
• Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.

  2006cited by this paper
• Inhibition of TNFα does not induce viral reactivation in patients with chronic hepatitis C infection: two cases

  2006cited by this paper
• An atypical varicella exanthem associated with the use of infliximab

  2006cited by this paper
• Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities.

  2006cited by this paper
• Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis.

  2006cited by this paper
• Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.

  2006cited by this paper
• Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

  2006cited by this paper
• Concomitant interferon-α therapy and tumor necrosis factor α inhibition for rheumatoid arthritis and hepatitis C

  2006cited by this paper
• Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

  2006cited by this paper
• C reactive protein: protecting from lupus in familial Mediterranean fever

  2005cited by this paper
• Cytomegalovirus Hepatitis Associated with Use of Anti-Tumor Necrosis Factor-α Antibody

  2005cited by this paper
• Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.

  2005cited by this paper
• Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis.

  2005cited by this paper
• Infliximab Therapy for Crohn’s Disease in a Patient with Chronic Hepatitis B

  2005cited by this paper
• Patients with Inflammatory Bowel Disease are at Risk for Vaccine-Preventable Illnesses

  2005cited by this paper
• Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy

  2005cited by this paper
• Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody.

  2005cited by this paper
• Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab.

  2005cited by this paper
• Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.

  2004cited by this paper
• Human immunodeficiency virus‐associated psoriasis and psoriatic arthritis treated with infliximab

  2004cited by this paper
• Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.

  2004cited by this paper
• Diagnosis, management, and treatment of hepatitis C

  2004cited by this paper
• Epstein-Barr Virus Viral Load in Crohn’s Disease: Effect of Immunosuppressive Therapy

  2004cited by this paper
• Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection

  2004cited by this paper
• A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

  2004cited by this paper
• Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis.

  2004cited by this paper
• Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.

  2004cited by this paper
• Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis

  2004cited by this paper
• Guidelines for immunizations in patients with inflammatory bowel disease.

  2004cited by this paper
• Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

  2004cited by this paper
• Genital condylomata in a patient receiving infliximab for Crohn’s disease

  2004cited by this paper
• Epstein–Barr virus and lymphoproliferative disorders after transplantation

  2004cited by this paper
• Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases.

  2004cited by this paper
• Disseminated primary varicella infection during infliximab treatment.

  2004cited by this paper
• Severe herpes zoster after infliximab infusion

  2004cited by this paper
• Disseminated Primary Varicella after Initiation of Infliximab for Crohn's Disease

  2004cited by this paper
• Pneumocystis carinii Pneumonia During Maintenance Anti–Tumor Necrosis Factor-&agr; Therapy with Infliximab for Crohn’s Disease

  2004cited by this paper

• Spontaneous reverse seroconversion in resolved hepatitis B infection.

  2025cites this paper
• Serological Profiles of Hepatitis B Virus in Patients With Crohn’s Disease Undergoing Anti-Tumor Necrosis Factor Alpha (TNFα) Therapy at Ibn Sina University Hospital, Rabat

  2024influential citation
• Expanding the scope of mast cell disease: Does mast cell‐derived TNF play a role in immune‐mediated chronic illness and autoimmunity?

  2024cites this paper
• Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV

  2023cites this paper
• Tumor necrosis factor-alpha blockade suppresses BK polyomavirus replication

  2022cites this paper
• [Guideline for the Treatment and Prevention of Infections Associated with Immunosuppressive Therapy for Autoimmune Diseases].

  2021cites this paper
• ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.

  2021cites this paper
• A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects

  2020cites this paper
• Reactivation of Epstein–Barr Virus Presenting as Massive Splenomegaly after Initiation of Golimumab Treatment

  2020cites this paper
• A comprehensive review of vaccination in patients with inflammatory bowel diseases: An Indian perspective

  2020cites this paper
• Successful treatment of severe perianal Crohn’s disease with infliximab in an HIV-positive patient

  2019cites this paper
• Therapie mit monoklonalen Antikörpern in der Gastroenterologie

  2019cites this paper
• Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

  2019cites this paper
• Cytomegalovirus reactivation in inflammatory bowel disease: an uncommon occurrence related to corticosteroid dependence

  2019cites this paper
• Practical Guidelines for Managing Patients With Psoriasis on Biologics: An Update

  2019cites this paper
• Viral infections in the biologic therapy era

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

  2018cites this paper
• Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen

  2018cites this paper
• Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review

  2017cites this paper
• Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

  2017cites this paper
• Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis

  2017cites this paper
• Management and Prevention of Herpes Zoster in the Immunocompromised Inflammatory Bowel Disease Patient: A Clinical Quandary

  2016cites this paper
• A Case Report of Severe Ulcerative Colitis in an HIV Patient

  2016cites this paper
• The Role of Tumour Necrosis Factor in Pulmonary Viral Infections

  2016cites this paper
• Convergent Transcription of Interferon-stimulated Genes by TNF-α and IFN-α Augments Antiviral Activity against HCV and HEV

  2016cites this paper
• Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS.

  2016cites this paper
• NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors.

  2016influential citation
• Etude de l’efficacité des stratégies d’immunothérapies actives anti-cytokine et évaluation des conséquences de la vaccination anti-TNF dans des modèles infectieux

  2016cites this paper
• Adverse Events During Anti-TNF&agr; Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies

  2016cites this paper
• Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts.

  2016cites this paper
• Updates in vaccination: recommendations for adult inflammatory bowel disease patients.

  2015cites this paper
• Gastroenterology and Hepatology Research

  2015cites this paper
• Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues

  2015cites this paper
• Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus

  2015cites this paper
• Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis

  2015cites this paper
• Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease: A Practical Case-based Approach

  2015cites this paper
• Current gene therapy using viral vectors for chronic pain

  2015cites this paper
• Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: a nationwide population‐based cohort study

  2015cites this paper
• Reactivation of latent viruses after treatment with biological therapies

  2014influential citation
• Review article: the intersection of mucosal pathophysiology in HIV and inflammatory bowel disease, and its implications for therapy

  2014influential citation
• Risk of infections of biological therapies with accent on inflammatory bowel disease.

  2014cites this paper
• Viral Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature

  2014cites this paper
• Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.

  2014cites this paper
• Statins, immunomodulation, and infections: a complex and unresolved relationship.

  2014cites this paper
• Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.

  2014cites this paper
• Stopping, Continuing, or Restarting Immunomodulators and Biologics When an Infection or Malignancy Develops

  2014cites this paper
• What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

  2014cites this paper
• New Insights and Treatments For VZV-induced Pain In a Rat Model of Postherpetic Neuralgia

  2014cites this paper
• Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part I. Risks associated with tumor necrosis factor-alfa antagonists.

  2014cites this paper
• Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy

  2014cites this paper
• Proactive infectious disease approach to dermatologic patients who are taking tumor necrosis factor-alfa antagonists: Part II. Screening for patients on tumor necrosis factor-alfa antagonists.

  2014cites this paper
• Current Practice of Anti-TNF-α Treatment in Inflammatory Bowel Disease: Results From A National Survey in Sweden

  2014cites this paper
• Ramsay-Hunt Syndrome in a patient with Crohn's disease under adalimumab: first case report.

  2014cites this paper
• Disseminated Varicella Zoster Virus Infection with Encephalitis in a UC Patient Receiving Infliximab.

  2013cites this paper
• Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.

  2013cites this paper
• The Influence of Anti-TNF Therapy on the Course of Chronic Hepatitis C Virus Infection in Patients with Inflammatory Bowel Disease

  2013cites this paper
• Diarylheptanoids and flavonoids from viscum album inhibit LPS-stimulated production of pro-inflammatory cytokines in bone marrow-derived dendritic cells.

  2013cites this paper
• Exacerbation of Verruca Vulgaris Associated with Etanercept in A Case of Ankylosing Spondylitis

  2013cites this paper
• Systematic review: macrophage activation syndrome in inflammatory bowel disease

  2013cites this paper
• Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

  2013cites this paper
• Prevention of infection caused by immunosuppressive drugs in gastroenterology

  2013cites this paper
• Hepatitis B and C reactivation with tumor necrosis factor inhibitors: synopsis and interpretation of screening and prophylaxis recommendations.

  2013cites this paper
• Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.

  2013cites this paper
• Natalizumab and cervical dysplasia Introduction

  2013cites this paper
• Varicella zoster virus infection in patients with inflammatory bowel disease.

  2013cites this paper
• Eruptive Condyloma Accuminata after Initiation of Infliximab Treatment for Folliculitis Decalvans

  2013cites this paper
• PROBIR NA OPORTUNISTIČKE INFEKCIJE I CIJEPLJENJE PRIJE POČETKA BIOLOŠKE TERAPIJE

  2013influential citation
• NUSPOJAVE I KONTRAINDIKACIJE ZA BIOLOŠKU TERAPIJU U UPALNIM BOLESTIMA CRIJEVA

  2013cites this paper
• Biological Treatment of Crohn’s Disease

  2013cites this paper
• Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.

  2013cites this paper
• Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

  2012cites this paper
• Efectos secundarios cutáneos de los fármacos antagonistas del factor de necrosis tumoral α

  2012cites this paper
• Simian Immunodeficiency Virus-Induced Alterations in Monocyte Production of Tumor Necrosis Factor Alpha Contribute to Reduced Immune Activation in Sooty Mangabeys

  2012cites this paper
• Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes

  2012cites this paper
• Infectious Complications of Anti-Tumour Necrosis Factor-α Therapy in Rheumatoid Arthritis

  2012cites this paper
• Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management.

  2012cites this paper
• Biologic Therapy of Crohn’s Disease: Infliximab

  2012cites this paper
• Biologics in oral medicine: principles of use and practical considerations.

  2012cites this paper
• Indian Society of Gastroenterology consensus on ulcerative colitis

  2012cites this paper
• Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.

  2012cites this paper
• Varicella zoster virus infection in inflammatory bowel disease

  2012cites this paper
• Quality improvement in gastroenterology clinical practice.

  2012cites this paper
• SIV-INDUCED ALTERATIONS IN MONOCYTE TNF-α PRODUCTION CONTRIBUTE

  2012cites this paper
• PERSPECTIVES IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Quality Improvement in Gastroenterology Clinical Practice

  2012cites this paper
• Prior varicella zoster virus exposure in IBD patients treated by anti‐TNFs and other immunomodulators: implications for serological testing and vaccination guidelines

  2012cites this paper
• Efficacy of tumour necrosis factor‐α antagonists in aphthous ulceration: review of published individual patient data

  2012cites this paper
• Liver diseases associated with anti‐tumor necrosis factor‐alpha (TNF‐&agr;) use for inflammatory bowel disease

  2011cites this paper
• Infections and the Liver

  2011cites this paper
• Biologics in Paediatric Crohn's Disease

  2011cites this paper
• A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease

  2011cites this paper
• The difficulties of managing severe hepatitis B virus reactivation

  2011cites this paper
• Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease

  2011influential citation
• Viral infections associated with the clinical use of monoclonal antibodies.

  2011influential citation
• TNF alpha antagonist therapy and safety monitoring.

  2011cites this paper
• The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy.

  2011cites this paper
• Genital human Papillomavirus infection in patients with autoimmune inflammatory diseases.

  2011cites this paper
• Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.

  2011cites this paper
• EBV hepatitis in a young Crohn's disease patient on prolonged remission with azathioprine.

  2011cites this paper
• Comment utiliser les biothérapies anti-TNF-α dans les maladies inflammatoires chroniques intestinales ?

  2011cites this paper
• Etanercept in the Treatment of Psoriasis: The Emerging Evidence of its Therapeutic Value

  2011cites this paper